OTLK logo

OTLK

Outlook Therapeutics Inc.

$0.85
-$0.24(-21.91%)
40
Overall
60
Value
33
Tech
28
Quality
Market Cap
$119.93M
Volume
18.31M
52W Range
$0.79 - $8.32
Target Price
$9.00
Order:

Income Statement

MetricTrendChart
2016
Sep
2017
Sep
2018
Sep
2019
Sep
2020
Sep
2021
Sep
2022
Sep
2023
Sep
2024
Sep
REVENUE
Total Revenue
$3.0M$3.8M$3.1M$8.1M----------
Total Revenue
$3.0M$3.8M$3.1M$8.1M----------
GROSS PROFIT
Gross Profit
$3.0M$3.8M$3.1M$8.1M----------
OPERATING EXPENSES
Operating Expenses
$-54.3M$-39.7M$-32.7M$-44.4M$36.8M$51.7M$63.1M$53.1M$71.7M
Research & Development
$32.8M$23.8M$20.4M$24.4M$26.3M$39.0M$42.3M$26.5M$41.8M
Research Expense
$32.8M$23.8M$20.4M$23.8M$26.3M$39.0M$42.3M$26.5M$41.8M
Selling, General & Administrative
$21.6M$15.9M$14.2M$9.4M$10.0M$12.8M$20.7M$26.7M$29.9M
General & Administrative Expenses
$21.6M$15.9M$14.2M$9.4M$10.0M$12.8M$20.7M$26.7M$29.9M
Salaries & Wages
$-98.2K----$-1.3M------$5.5M$5.4M
Depreciation & Amortization
$-2.4M$-2.7M$-3.1M$-3.4M$219.4K$163.6K$163.6K----
Depreciation & Amortization
$-2.4M$-2.7M$-3.1M$-3.4M$219.4K$163.6K$163.6K----
Amortization
--------$183.0K--------
Other Operating Expenses
$-100.0K$-497.5K----$1.3M$112.0K$48.0K$46.3K$58.1K
OPERATING INCOME
Operating income
$-51.3M$-35.9M$-31.5M$-25.7M$-36.8M$-51.7M$-63.1M$-53.1M$-71.7M
EBITDA
$-49.0M$-30.0M$-26.8M$-33.9M$-36.2M$-52.0M$-64.4M$-58.9M$-75.2M
NON-OPERATING ITEMS
Interest Expense (Non-Operating)
$1.9M$5.6M$3.9M$3.5M$1.8M$936.1K$1.5M$1.4K$116
Intinc
--------------$971.5K$906.1K
Net Non-Operating Interest Income/Expense
$-1.9M$-5.6M$-3.9M$-3.5M$-1.8M$-936.1K$-1.5M$971.5K$906.1K
Gain on Sale of Securities
----$-4.2M------------
Other Income/Expense
--$-3.2M$204.6K$-1.8M$1.9M$498.5K$-1.5M$537.7K$-38.5M
Other Special Charges
--$3.2M$-204.6K$1.8M$-1.7M$-452.1K$-559.6K$-526.7K$38.6M
SPECIAL ITEMS
Restructring And Mn A Income
--------$-900.0K--------
Special Income Charges
----$-1.9M$-11.3M$-527.6K--------
Impairment of Capital Assets
------$11.3M$527.6K--------
PRE-TAX INCOME
EBIT
$-51.3M$-32.7M$-29.8M$-37.3M$-36.8M$-52.2M$-64.6M$-59.0M$-75.4M
Pre-Tax Income
$-53.2M$-38.3M$-33.7M$-37.9M$-38.5M$-53.2M$-66.0M$-59.0M$-75.4M
INCOME TAX
Tax Provision
$103.0K$501.5K$-3.6M$-3.4M$-3.3M$2.0K$2.8K$2.8K$2.8K
NET INCOME
Net Income
$-53.3M$-38.8M$-32.0M$-35.1M$-35.2M$-53.2M$-66.1M$-59.0M$-75.4M
Net Income (Continuing Operations)
$-53.3M$-38.8M$-32.0M$-35.1M$-35.2M$-53.2M$-66.1M$-59.0M$-75.4M
Net Income (Discontinued Operations)
$-53.3M$-38.8M$-32.0M$-35.1M$-35.2M$-53.2M$-66.1M$-59.0M$-75.4M
Net Income (Common Stockholders)
$-63.1M$-40.0M$-48.0M$-36.0M$-48.9M$-53.2M$-66.1M$-59.0M$-75.4M
Normalized Income
----------$-42.0M----$-74.6M
TOTALS
Total Expenses
$-54.3M$-39.7M$-32.7M$-44.4M$36.8M$51.7M$63.1M$53.1M$71.7M
SHARE & EPS DATA
Average Shares Outstanding
$107.6K$3.0M$4.9M$18.2M$72.6M$152.7M$10.6M$12.5M$18.5M
Average Shares Outstanding (Diluted)
$90.8K$3.0M$4.9M$17.8M$72.6M$152.7M$10.6M$12.5M$18.5M
Shares Outstanding
$147.4K$3.2M$10.6M$30.1M$6.4M$224.3M$44.4M$13.0M$24.9M
Basic EPS
--$-13.36$-9.76--$-0.67$-0.35$-6.2$-4.8$-4.06
Basic EPS (Continuing Operations)
--------$-0.67$-0.35$-6.2$-4.8$-4.06
Diluted EPS
$-587.2$-14.4$-9.76$-1.98$-0.67$-0.35$-6.2$-4.8$-4.06
Diluted EPS (Continuing Operations)
----------$-0.35$-6.2$-4.8$-4.06
OTHER METRICS
Accretion On Preferred Stock
$2.5M----------------
Accrued Preferred Stock Dividends
$7.4M$1.2M$16.0M$890.9K$13.5M--------
Development Expense
------$625.0K----------
Earnings from equity interest
----------$-46.3K$-48.7K$-11.0K$-100.7K
Earnings From Equity Interest Net Of Tax
----------$-46.3K$-48.7K$-11.0K$-100.7K
Gain On Sale Of P P E
--------$-680.0K$552.3K------
Interest Expense Operating
------$-2.8M$-914.0K--------
Minority Interests
$654.4K----------------
Other Gand A
$21.6M$15.9M$14.2M$9.4M$10.0M$12.8M$20.7M$26.7M$29.9M
Other Impairment Of Capital Assets
--------$166.1K--------
Otherunder Preferred Stock Dividend
$9.8M$1.2M$16.0M$890.9K$13.5M--------
Preferred Stock Dividends
$9.8M$1.2M$16.0M$890.9K$13.5M--------
Rent And Landing Fees
$21.6M$15.9M$14.2M$9.4M----------
Othspecchg
----$1.9M------------
Restruct
--------$-900.0K--------

Financial data is updated quarterly and may not reflect the most recent earnings.

ABCD
1SymbolPriceChangeVol
2OTLK$0.85-21.9%18.31M
3
4
5
6

Get Outlook Therapeutics Inc. Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.